DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic
studies of three asparaginase preparations. J Clin
Oncol, 1993, 11:1780–1786.
Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison
of native Escherichia coli asparaginase and polyethylene
glycol conjugated asparaginase for treatment of children with
newly diagnosed standard-risk acute lymphoblastic leukemia:
A Children’s Cancer Group study. Blood, 2002, 99: 1986–1994.
Baker DK, Relling MV, Pui CH, et al. Increased teniposide clearance
with concomitant anticonvulsant therapy. J Clin Oncol,
1992, 10:311–315.
Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism
and excretion of 14 C-temozolomide following oral administration
to patients with advanced cancer. Clin Cancer Res, 1999,
5:309–317.
Barbour KW, Berger SH, Berger FG. Single amino acid substitution
defines a naturally occurring genetic variant of human
thymidylate synthase. Mol Pharmacol, 1990, 37:515–518.
Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics
of estramustine phosphate. Clin Pharmacokinet,
1998, 34:163–172.
Berlin NI, Rall D, Mead JA, et al. Folic acid antagonist. Effects
on the cell and the patient. Combined clinical staff conference
at the National Institutes of Health. Ann Intern Med, 1963,
59:931–956.
Blakley RL, Sorrentino BP. In vitro mutations in dihydrofolate
reductase that confer resistance to methotrexate: Potential for
clinical application. Hum Mutat, 1998, 11:259–263.
Bleyer WA. The clinical pharmacology of methotrexate: New
applications of an old drug. Cancer, 1978, 41:36–51.
Boccardo F, Cannata D, Rubagotti A, et al. Prophylaxis of superficial
bladder cancer with mitomycin or interferon alfa-2b:
Results of a multicentric Italian study. J Clin Oncol, 1994,
12:7–13.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone
deacetylase inhibitors. Nat Rev Drug Discov, 2006,
5:769–784.
Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and
development of clofarabine: A nucleoside analogue for treating
cancer. Nat Rev Drug Discov, 2006, 5:855–863.
Brawley OW, Cornelius LJ, Edwards LR, et al. National
Institutes of Health Consensus Development Conference statement:
Hydroxyurea treatment for sickle cell disease. Ann
Intern Med, 2008, 148:932–938.
Broome JD. L-Asparaginase: Discovery and development as a
tumor-inhibitory agent. Cancer Treat Rep, 1981, 65(suppl):
111–114.
Burger RM. Cleavage of nucleic acids by bleomycin. Chem Rev,
1998, 98:1153–1169.
Cabral FR. Isolation of Chinese hamster ovary cell mutants
requiring the continuous presence of Taxol for cell division. J
Cell Biol, 1983, 97:22–29.
Cahill DP, Codd PJ, Batchelor TT, et al. MSH6 inactivation and
emergent temozolomide resistance in human glioblastomas.
Clin Neurosurg, 2008, 55:165–171.
Cai J, Damaraju VL, Groulx N, et al. Two distinct molecular
mechanisms underlying cytarabine resistance in human
leukemic cells. Cancer Res, 2008, 68:2349–2357.
Cardoen S, Van Den Neste E, Small C, et al. Resistance to 2-chloro-
2′-deoxyadenosine of the human B-cell leukemia cell line
EHEB. Clin Cancer Res, 2001, 7:3559–3566.
Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic
complications in childhood acute lymphoblastic leukemia: A
meta-analysis of 17 prospective studies comprising 1752 pediatric
patients. Blood, 2006, 108:2216–2222.
Chen CC, Taniguchi T, D’Andrea A. The Fanconi anemia (FA)
pathway confers glioma resistance to DNA alkylating agents.
J Mol Med, 2007, 85:497–509.
Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics
of cyclophosphamide in patients with metastatic
breast cancer receiving high-dose chemotherapy followed by
autologous bone marrow transplantation. Cancer Res, 1995,
55:810–816. Erratum in: Cancer Res, 1995, 55:1600.
Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology
of LY231514 (MTA): A comparison with
methotrexate, LY309887 and raltitrexed for their effects on
intracellular folate and nucleoside triphosphate pools in
CCRF-CEM cells. Br J Cancer, 1998, 78(suppl):27–34.
Chlenski A, Cohn S. Modulation of matrix remodeling by
SPARC in neoplastic progression. Semin Cell Dev Biol, 2010,
21:55–65.
Chu E, Koeller DM, Casey JL, et al. Autoregulation of human
thymidylate synthase messenger RNA translation by thymidylate
synthase. Proc Natl Acad Sci U S A, 1991, 88:8977–8981.
Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel.
Clin Pharmacokinet, 1999, 36:99–114.
Cokic VP, Smith RD, Beleslin-Cokic B, et al. Hydroxyurea
induces fetal hemoglobin by the nitric oxide-dependent activation
of soluble guanylyl cyclase. J Clin Invest, 2003,
111:231–239.
Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted
survival comparison of sustained-release cytosine arabinoside
versus intrathecal methotrexate for treatment of solid tumor
neoplastic meningitis. Cancer, 2003, 97:3053–3060.
Collins SJ. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Curr Opin Hematol, 2008, 15:346–351.
Cordoba R, Ramirez E, Lei SH, et al. Hypercalcemia due to an
interaction of all-trans retinoic acid (ATRA) and itraconazole
therapy for acute promyelocytic leukemia successfully treated
with zoledronic acid. Eur J Clin Pharmacol, 2008,
64:1031–1032.
Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by
human liver microsomes: Identification of cytochrome P450
isozymes involved in its biotransformation. Cancer Res, 1994,
54:386–392.
Curt GA, Jolivet J, Carney DN, et al. Determinants of the sensitivity
of human small-cell lung cancer cell lines to methotrexate.
J Clin Invest, 1985, 76:1323–1329.
Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity:
Its relationship to renal dysfunction. Med Pediatr Oncol,
1984, 12:313–317.
De Gramont A, Louvet C, Andre T, et al. A review of GERCOD trials
of bimonthly leucovorin plus 5-fluorouracil 48-h continuous
infusion in advanced colorectal cancer: Evolution of a regimen.
Groupe d’Etude et de Recherche sur les Cancers de l’Ovaire et
Digestifs (GERCOD). Eur J Cancer, 1998, 34:619–626.
de Haas EC, Zwart N, Meijer C, et al. Variation in bleomycin
hydrolase gene is associated with reduced survival after
chemotherapy for testicular germ cell cancer. J Clin Oncol,
2008, 26:1817–1823.
de Wolf C, Jansen R, Yamaguchi H, et al. Contribution of the
drug transporter ABCG2 (breast cancer resistance protein) to
1725
CHAPTER 61
CYTOTOXIC AGENTS